GM 1892 clinical trials
Also written CX-01, Dociparstat sodium and PGX-100.
How each study uses GM 1892 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2013 | 1 |
| 2016 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses GM 1892 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid LeukemiaCompletedPhase 2ChimerixNCT02873338Written as Dociparstat sodiumHow we know
- A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid LeukemiaCompletedPhase 1ChimerixNCT02056782Written as Dociparstat sodiumHow we know
- Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory FailureTerminatedPhase 2/3ChimerixNCT04389840Written as Dociparstat sodiumHow we know
- A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPDTerminatedPhase 2ChimerixNCT00457951Written as Open-LabelHow we know
Codes
What other systems call GM 1892 · ClinicalTrials.gg INT003862
- MeSH (NLM) C094917GM 1892One source NLM
- UNII (FDA) 4O75889WF4DOCIPARSTAT SODIUMConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C094917 | GM 1892 | One source NLM |
| UNII (FDA) | 4O75889WF4 | DOCIPARSTAT SODIUM | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.